The target population was a clear priority from the original phase 1 study, where BRCA1/BRCA2 mutation carriers were the predominant responders, leading to a BRCA1/BRCA2 expansion (27), with promising activity in ovarian cancer (28), which was subsequently confirmed in phase 2 (29). Here, BRCA2 is linked to ovarian cancer.